“Sensitivity of KRAS-Mutated Non-Small Cell Lung Cancer to a Combination of MEK Kinase Inhibitor (Trametinib) and Autophagy Inhibitor (Hydroxychloroquine) in a Tissue Explant Model”. Voprosy Onkologii, vol. 72, no. 1, Mar. 2026, p. OF-2403, https://doi.org/10.37469/0507-3758-2026-72-1-OF-2403.